OTC division's new responsibilities under FDA guidelines should be phased in -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC DIVISION PHASE-IN OF Rx-TO-OTC SWITCH POST-APPROVAL OVERSIGHT urged by the Nonprescription Drug Manufacturers Association in an Aug. 16 letter to Murray Lumpkin, MD, deputy director for review management at FDA's Center for Drug Evaluation & Research. Commenting on a recently released draft of FDA internal guidelines that would expand the OTC division's purview over NDAed OTCs, NDMA suggested "staged implementation of [the division's] responsibilities in the post-approval oversight of OTC NDAs (e.g., starting with ODE V) in order to ensure a smooth stepwise implementation."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning